I can explain it and have previously. There were multiple reagents used in one of 2 potency assays used in the trial. One of these reagents had inadequate QA and as a result was too variable in quality giving poor results. SI stated to me after the AGM that he thought the original assay was superior to the one that was accepted for the Adult trial. Analyzing the original trial data using potency assays with proper QA gives acceptable new data for consideration of the successful phase III trial.
I can explain it and have previously. There were multiple...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
-0.083(6.71%) |
Mkt cap ! $1.321B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.20 | $1.15 | $6.695M | 5.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 208612 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.15 | 31934 | 10 |
View Market Depth
| Last trade - 11.56am 30/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.16 |
Change
-0.083 ( 6.03 %) |
||||
| Open | High | Low | Volume | ||
| $1.20 | $1.20 | $1.15 | 604909 | ||
| Last updated 12.17pm 30/05/2024 ? | |||||
| MSB (ASX) Chart |